Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022)
Taysha Gene Therapies (TSHA) posted Net Equity Issued and Repurchased of $40000.0 for Q2 2022, down 99.94% sequentially from $66.2 million in Q4 2020.
Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022) Analysis & Trends
Taysha Gene Therapies has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $40000.0 in Q2 2022.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $40000.0 in Q2 2022, while the trailing twelve-month figure through Sep 2023 was $40000.0 (down 99.95% YoY) and the FY2023 annual result came in at $500000.0, down 95.7% from the prior year.
- Net Equity Issued and Repurchased eased to $40000.0 in Q2 2022 per TSHA's latest filing, from $66.2 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $66.2 million in Q4 2020 and troughed at $40000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.08 Mn |
| Dec 31, 2022 | 16.08 Mn |
| Jun 30, 2022 | 40,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Dec 31, 2020 | 66.25 Mn |
| Dec 31, 2020 | 66.25 Mn |
| Sep 30, 2020 | 10.97 Mn |
| Sep 30, 2020 | 10.97 Mn |
| Jun 30, 2020 | 600,000.00 |
| Jun 30, 2020 | 600,000.00 |
| Mar 31, 2020 | 18.00 Mn |
| Mar 31, 2020 | 18.00 Mn |